ARAVAX
Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy. The company is using their proprietary technology to reset the immune system to tolerate peanut without evoking allergic reactions during treatment. Aravax was founded in May 2015 through acquisition of intellectual property developed by Alfred Health and Monash University. Aravax has its headquarters in Melbourne, Australia.
ARAVAX
Industry:
Biotechnology Health Care Wellness
Founded:
2015-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.aravax.com.au
Total Employee:
11+
Status:
Active
Contact:
+610396570700
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Mobile Non Scaleable Content Euro Microsoft Exchange Online
Similar Organizations
UbiVac
UbiVac is a clinical-stage biotechnology company engaged in the research and development of therapeutic vaccines to combat cancer.
Current Employees Featured
Founder
Investors List
Medical Research Commercialisation Fund (MRCF)
Medical Research Commercialisation Fund (MRCF) investment in Seed Round - Aravax
Brandon Capital Partners
Brandon Capital Partners investment in Seed Round - Aravax
Official Site Inspections
http://www.aravax.com.au
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
